Login to Your Account



Clinic Roundup


Monday, December 13, 2010
• Arena Pharmaceuticals Inc., of San Diego, started dosing in a Phase I trial of APD811, an oral candidate designed to target the prostacyclin receptor for treatment of pulmonary arterial hypertension. The study is expected to enroll up to 72 healthy adult volunteers to test single-ascending doses of the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription